Literature DB >> 30354665

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Silvio E Inzucchi1, Mikhail Kosiborod2, David Fitchett3, Christoph Wanner4, Uwe Hehnke5, Stefan Kaspers5, Jyothis T George5, Bernard Zinman6.   

Abstract

Entities:  

Keywords:  blood glucose; sodium-glucose transporter 2; treatment outcome; type 2 diabetes mellitus

Mesh：

Substances：

Year:  2018        PMID： 30354665     DOI： 10.1161/CIRCULATIONAHA.118.035759

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  38 in total

1.  [Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure].

Authors:  L Lauder; S Ewen; I E Emrich; M Böhm; F Mahfoud
Journal:  Herz       Date:  2019-11       Impact factor: 1.443

2.  2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  John B Buse; Deborah J Wexler; Apostolos Tsapas; Peter Rossing; Geltrude Mingrone; Chantal Mathieu; David A D'Alessio; Melanie J Davies
Journal:  Diabetologia       Date:  2020-02       Impact factor: 10.122

3.  Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial.

Authors:  Kasia J Lipska; Neda Laiteerapong
Journal:  N Engl J Med       Date:  2019-06-06       Impact factor: 91.245

4.  Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.

Authors:  Wan-Chuan Tsai; Shih-Ping Hsu; Yen-Ling Chiu; Ju-Yeh Yang; Mei-Fen Pai; Mei-Ju Ko; Yu-Kang Tu; Kuan-Yu Hung; Kuo-Liong Chien; Yu-Sen Peng; Hon-Yen Wu
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

Review 5.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

Review 6.  Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.

Authors:  Rachel J Perry; Gerald I Shulman
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

Review 7.  Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.

Authors:  Melanie Nana; Holly Morgan; L N Rao Bondugulapati
Journal:  Heart Fail Rev       Date:  2021-07       Impact factor: 4.214

8.  Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats.

Authors:  Jacob Marthinsen Seefeldt; Thomas Ravn Lassen; Marie Vognstoft Hjortbak; Nichlas Riise Jespersen; Frederikke Kvist; Jakob Hansen; Hans Erik Bøtker
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

Review 9.  Cardiovascular disease in diabetes, beyond glucose.

Authors:  Robert H Eckel; Karin E Bornfeldt; Ira J Goldberg
Journal:  Cell Metab       Date:  2021-07-21       Impact factor: 31.373

10.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Katherine R Tuttle; Frank C Brosius; Matthew A Cavender; Paola Fioretto; Kevin J Fowler; Hiddo J L Heerspink; Tom Manley; Darren K McGuire; Mark E Molitch; Amy K Mottl; Leigh Perreault; Sylvia E Rosas; Peter Rossing; Laura Sola; Volker Vallon; Christoph Wanner; Vlado Perkovic
Journal:  Diabetes       Date:  2020-10-26       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.